Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3008894 | 0.92 | AR (0.56) | ARSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL3009246 | 0.92 | SMN1; SMN2 (0.49) | ARSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL2999887 | 0.89 | AR (0.45) | ARSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL3017654 | 0.89 | AR (0.44) | ARSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL3017803 | 0.88 | AR (0.44) | ARSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL3009438 | 0.87 | SMN1; SMN2 (0.47) | ARSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL3010676 | 0.86 | AR (0.44) | ARSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL3013809 | 0.85 | AR (0.44) | ARSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL3009239 | 0.85 | SMN1; SMN2 (0.45) | ARSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL3019476 | 0.85 | AR (0.57) | ARSMN1; SMN2NPC1RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | AR 3801/4885SMN1; SMN2 1/4885NPC1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.